According to the latest market report published by Credence Research, Inc. Human Rabies Treatment  Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 the global Human Rabies Treatment  market was valued at US$ 2.71 Bn in 2016, and is expected to reach US$ 4.32 Bn by 2025, expanding at a CAGR of  5.3% from 2017 to 2025.

Browse the full report Human Rabies Treatment Market - Growth, Future Prospects and Competitive Analysis, 2017 2025 report athttp://www.credenceresearch.com/report/human-rabies-treatment-market

Market Insights

Rabies is a fatal neurological disease, usually spread to humans through the bite of a rabid animal, and it is a persistent global problem. Some factors such as growing number of preventive vaccines and rising treatment awareness are prime factors that are driving the growth of human rabies treatment market globally. For the purpose of the study global human rabies treatment market is segmented on the basis of product type such as cell culture vaccines, rabies immunoglobulin, nerve tissue vaccines and other. It is estimated that, cell culture vaccines will grow significantly during forecast period due to its safety, higher immunogenicity, fewer adverse effects and negligible allergic reactions compared to other types of human rabies treatment. Based on treatment type, global human rabies treatment market is categorized as pre-exposure immunization and post-exposure prophylaxis and it is observed that, demand for post-exposure prophylaxis is increasing in developing countries because post-exposure prophylaxis is the only safe and effective treatment available in market to prevent exposed persons from acquiring rabies infection. According to World Health Organization (WHO), every year more than 15 million people worldwide receive a post-bite vaccination. Currently demand for the prophylaxis treatment is highest in North America due to developed healthcare infrastructure and high treatment awareness.  It is estimated that, Asia-Pacific will show significant market growth during forecast period due to increasing treatment awareness, developing economic condition, populous countries and increasing government initiatives in prevention of rabies.

Market Competition Assessment:

The Human Rabies Treatment market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as Bio Med Pvt. Ltd., Biological E, Cadila Healthcare, CSC Pharmaceuticals International, GlaxoSmithKline GmbH, Grifols S.A., Kamada Ltd., Kedrion S.p.A., Novartis International AG, Sanofi Pasteur SA, Serum institute of India and other. 

Key Market Movements:

• Factors such as increasing treatment awareness and rising government initiatives in prevention of rabies are prime factors that driving the growth of human rabies treatment market during forecast period.
• Poor patient compliance to medication and undeveloped healthcare infrastructure in some Asian and African countries where highest number of affected population is located are negatively impacting the market growth of human rabies treatment.

Browse the full report Human Rabies Treatment Market - Growth, Future Prospects and Competitive Analysis, 2017 2025 report athttp://www.credenceresearch.com/report/human-rabies-treatment-market

 Latest Reports:

Airfield Lighting Market: http://www.credenceresearch.com/press/global-Custom T-shirt Printing-treatment-market

Rabies vaccine is a vaccine used to prevent rabies.  There are a number of vaccines available that are both safe and effective.[1] They can be used to prevent rabies before and for a period of time after exposure to the virus such as by a dog or bat bite. The immunity that develops is long lasting after a full course. Doses are usually given by injection into the skin or muscle.  After exposure vaccination is typically used along with rabies immunoglobulin.  It is recommended that those who are at high risk of exposure be vaccinated before potential exposure.  Vaccines are effective in humans and other animals. Vaccinating dogs is very effective in preventing the spread of rabies to humans.

Rabies vaccines may be safely used in all age groups. About 35 to 45 percent of people develop a brief period of redness and pain at the injection site.  About 5 to 15 percent of people may have fever, headaches, or nausea.  After exposure to rabies there is no contraindication to its use. Most vaccines do not contain thimerosal. Vaccines made from nerve tissue are used in a few countries, mainly in Asia and Latin America, but are less effective and have greater side effects. Their use is thus not recommended by the World Health Organization.

The first rabies vaccine was introduced in 1885, which was followed by an improved version in 1908. Millions of people globally have been vaccinated and it is estimated that this saves more than 250,000 people a year. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] The wholesale cost in the developing world is between 44 and 78 USD for a course of treatment as of 2014. In the United States a course of rabies vaccine is more than 750 USD. Source: Wikipedia

Blog: https://globenewswire.com/news-release/2018/03/08/1418682/0/en/Custom-T-shirt-Printing-Market-is-Expected-To-Cross-US-10-Billion-by-2025-Credence-Research.html

About:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared for this task.

Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com